Management of bone metastases in patients with castration-resistant prostate cancer

Richard Cathomas; Zoltan Bajory; Mounira Bouzid; Ahmed El Ghoneimy; Silke Gillessen; Frederico Goncalves; Gabriel Kacso; Gero Kramer; Piotr Milecki; Dalibor Pacik; Wahid Tantawy; Krzystof Lesniewski-Kmak

doi:10.1159/000358258

Management of bone metastases in patients with castration-resistant prostate cancer

Richard Cathomas, Zoltan Bajory, Mounira Bouzid, Ahmed El Ghoneimy, Silke Gillessen, Frederico Goncalves, Gabriel Kacso, Gero Kramer, Piotr Milecki, Dalibor Pacik, Wahid Tantawy, Krzystof Lesniewski-Kmak

Division of Cancer Sciences (L5)

Cantonal Hospital Graubünden

Research output: Contribution to journal › Review article › peer-review

Abstract

Bone metastases are a very common problem in prostate cancer. They are associated with considerable morbidity, adversely affect quality of life and frequently lead to advanced bone events (so-called skeletal-related events, SREs); SREs include fractures, spinal cord compression and the requirement for bone surgery or bone radiation. The aim of this paper was to evaluate currently available treatment options in the prevention and management of SREs and bone metastases in men with castration-resistant prostate cancer and to outline the importance of interdisciplinary management strategies. It also discusses the diagnostic workup of osseous metastases and practical considerations for the utilization of bone-targeted therapies in accordance with current guidelines to provide a consensus for special and/or difficult clinical situations.

Original language	English
Pages (from-to)	377-386
Number of pages	10
Journal	Urologia Internationalis
Volume	92
Issue number	4
DOIs	https://doi.org/10.1159/000358258
Publication status	Published - 2014

Keywords

Antibodies, Monoclonal, Humanized/therapeutic use
Bone Density Conservation Agents/therapeutic use
Bone Neoplasms/pathology
Bone and Bones/pathology
Denosumab
Diphosphonates/therapeutic use
Humans
Imidazoles/therapeutic use
Interdisciplinary Communication
Male
Medical Oncology/standards
Neoplasm Metastasis
Prostatic Neoplasms, Castration-Resistant/pathology
Quality of Life
Spinal Cord Compression
Treatment Outcome
Zoledronic Acid

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000358258

Cite this

@article{b388031ec4ff436baff4b19518a81f2e,

title = "Management of bone metastases in patients with castration-resistant prostate cancer",

abstract = "Bone metastases are a very common problem in prostate cancer. They are associated with considerable morbidity, adversely affect quality of life and frequently lead to advanced bone events (so-called skeletal-related events, SREs); SREs include fractures, spinal cord compression and the requirement for bone surgery or bone radiation. The aim of this paper was to evaluate currently available treatment options in the prevention and management of SREs and bone metastases in men with castration-resistant prostate cancer and to outline the importance of interdisciplinary management strategies. It also discusses the diagnostic workup of osseous metastases and practical considerations for the utilization of bone-targeted therapies in accordance with current guidelines to provide a consensus for special and/or difficult clinical situations.",

keywords = "Antibodies, Monoclonal, Humanized/therapeutic use, Bone Density Conservation Agents/therapeutic use, Bone Neoplasms/pathology, Bone and Bones/pathology, Denosumab, Diphosphonates/therapeutic use, Humans, Imidazoles/therapeutic use, Interdisciplinary Communication, Male, Medical Oncology/standards, Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant/pathology, Quality of Life, Spinal Cord Compression, Treatment Outcome, Zoledronic Acid",

author = "Richard Cathomas and Zoltan Bajory and Mounira Bouzid and {El Ghoneimy}, Ahmed and Silke Gillessen and Frederico Goncalves and Gabriel Kacso and Gero Kramer and Piotr Milecki and Dalibor Pacik and Wahid Tantawy and Krzystof Lesniewski-Kmak",

note = "{\textcopyright} 2014 S. Karger AG, Basel.",

year = "2014",

doi = "10.1159/000358258",

language = "English",

volume = "92",

pages = "377--386",

journal = "Urologia Internationalis",

issn = "0042-1138",

publisher = "S. Karger AG",

number = "4",

}

TY - JOUR

T1 - Management of bone metastases in patients with castration-resistant prostate cancer

AU - Cathomas, Richard

AU - Bajory, Zoltan

AU - Bouzid, Mounira

AU - El Ghoneimy, Ahmed

AU - Gillessen, Silke

AU - Goncalves, Frederico

AU - Kacso, Gabriel

AU - Kramer, Gero

AU - Milecki, Piotr

AU - Pacik, Dalibor

AU - Tantawy, Wahid

AU - Lesniewski-Kmak, Krzystof

PY - 2014

Y1 - 2014

N2 - Bone metastases are a very common problem in prostate cancer. They are associated with considerable morbidity, adversely affect quality of life and frequently lead to advanced bone events (so-called skeletal-related events, SREs); SREs include fractures, spinal cord compression and the requirement for bone surgery or bone radiation. The aim of this paper was to evaluate currently available treatment options in the prevention and management of SREs and bone metastases in men with castration-resistant prostate cancer and to outline the importance of interdisciplinary management strategies. It also discusses the diagnostic workup of osseous metastases and practical considerations for the utilization of bone-targeted therapies in accordance with current guidelines to provide a consensus for special and/or difficult clinical situations.

AB - Bone metastases are a very common problem in prostate cancer. They are associated with considerable morbidity, adversely affect quality of life and frequently lead to advanced bone events (so-called skeletal-related events, SREs); SREs include fractures, spinal cord compression and the requirement for bone surgery or bone radiation. The aim of this paper was to evaluate currently available treatment options in the prevention and management of SREs and bone metastases in men with castration-resistant prostate cancer and to outline the importance of interdisciplinary management strategies. It also discusses the diagnostic workup of osseous metastases and practical considerations for the utilization of bone-targeted therapies in accordance with current guidelines to provide a consensus for special and/or difficult clinical situations.

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Bone Density Conservation Agents/therapeutic use

KW - Bone Neoplasms/pathology

KW - Bone and Bones/pathology

KW - Denosumab

KW - Diphosphonates/therapeutic use

KW - Humans

KW - Imidazoles/therapeutic use

KW - Interdisciplinary Communication

KW - Male

KW - Medical Oncology/standards

KW - Neoplasm Metastasis

KW - Prostatic Neoplasms, Castration-Resistant/pathology

KW - Quality of Life

KW - Spinal Cord Compression

KW - Treatment Outcome

KW - Zoledronic Acid

U2 - 10.1159/000358258

DO - 10.1159/000358258

M3 - Review article

C2 - 24802278

SN - 0042-1138

VL - 92

SP - 377

EP - 386

JO - Urologia Internationalis

JF - Urologia Internationalis

IS - 4

ER -

Management of bone metastases in patients with castration-resistant prostate cancer

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this